All News

17 September 2009

Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics for novel treatments for oncology indicationsAntibodies

16 September 2009

Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral MucositisAntibodies

15 September 2009

Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)Antibodies

15 September 2009

Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired PneumoniaAntibodies

14 September 2009

Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer DiscontinuedAntibodies

11 September 2009

Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial DataAntibodies

9 September 2009

XOMA Announces $6 Million Antibody Discovery Collaboration With Arana TherapeuticsAntibodies

9 September 2009

ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche GroupAntibodies

8 September 2009

MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering PharmaAntibodies

7 September 2009

Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License ApplicationAntibodies

4 September 2009

FDA Approves ZEVALIN(R) Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin’s LymphomaAntibodies

3 September 2009

Two New Antibodies Found to Cripple HIVAntibodies

3 September 2009

MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemiaAntibodies

2 September 2009

Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine’s Cotara(R) for Treatment of Brain CancerAntibodies

1 September 2009

Ablynx Initiates Phase II Clinical Trial for Alx-0081Antibodies

1 September 2009

Patient recruitment in Phase III registration trial with REDECTANE® successfully completedAntibodies

28 August 2009

Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016Antibodies

27 August 2009

START OF THE FIRST PHASE II CLINICAL TRIAL WITH MONOCLONAL ANTIBODY IPH 2101 SUPPORTED BY A NEW 2.9 MILLIONS EUROS FINANCING FROM OSEOAntibodies

27 August 2009

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)Antibodies

26 August 2009

Dyax Announces Developments in Licensing and Funded Research ProgramAntibodies

26 August 2009

GENMAB ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ARZERRA™ IN FRONT LINE NHLAntibodies

24 August 2009

Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin LymphomaAntibodies

24 August 2009

Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthmaAntibodies

24 August 2009

Lpath Achieves Merck Serono MilestoneAntibodies

18 August 2009

Lpath Completes Enrollment of Patients in iSONEP(TM) Phase 1 Clinical TrialAntibodies

18 August 2009

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical DevelopmentAntibodies

18 August 2009

GLAXOSMITHKLINE AND GENMAB ANNOUNCE RESULTS FROM A STUDY OF ARZERRA IN RITUXIMAB REFRACTORY FOLLICULAR NHLAntibodies

18 August 2009

Crucell Receives NIH Award for the Development of Influenza Monoclonal AntibodiesAntibodies

17 August 2009

Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast CancerAntibodies

17 August 2009

Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Her3-Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Report Package: Claudin 18.2-Targeted Immunotherapeutics

B7-H4 Targeted Antibody Therapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists